IT Tech Packaging Inc(ITP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ITP IT Tech Packaging Inc

Pre-Mkt 08-04 08:18:40 EDT

0.1790

+0.0040

+2.29%

盘前0.1760

-0.0030-1.68%

08:06 EDT

High0.1835	Low0.1750	Vol414.58K
Open0.1800	D1 Closing0.1750	Amplitude4.86%
Mkt Cap3.04M	Tradable Cap2.94M	Total Shares16.97M
T/O74.35K	T/O Rate2.52%	Tradable Shares16.42M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ITP","market":"US","secType":"STK","nameCN":"IT Tech Packaging Inc","latestPrice":0.179,"timestamp":1785787200000,"preClose":0.175,"halted":0,"volume":414576,"hourTrading":{"tag":"盘前","latestPrice":0.176,"preClose":0.179,"latestTime":"08:06 EDT","volume":10728,"amount":1888.128,"timestamp":1785845160570,"change":-0.003,"changeRate":-0.01676,"amplitude":0},"delay":0,"changeRate":0.022857142857142878,"floatShares":16423703,"shares":16965420,"eps":-0.861876,"marketStatus":"Pre-Mkt","change":0.004,"latestTime":"08-04 08:18:40 EDT","open":0.18,"high":0.1835,"low":0.175,"amount":74345.01445008,"amplitude":0.048571,"askPrice":0.1943,"askSize":100,"bidPrice":0.161,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.861876,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1785850200000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"AMEX","adjPreClose":0.179,"preHourTrading":{"tag":"盘前","latestPrice":0.176,"preClose":0.179,"latestTime":"08:06 EDT","volume":10728,"amount":1888.128,"timestamp":1785845160570,"change":-0.003,"changeRate":-0.01676,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":0.1757,"preClose":0.179,"latestTime":"19:59 EDT","volume":10934,"amount":1942.4967,"timestamp":1785801545625,"change":-0.0033,"changeRate":-0.018436,"amplitude":0.032402},"volumeRatio":2.490523325987953,"impliedVol":1.4182,"impliedVolPercentile":0.42},"requestUrl":"/m/hq/s/ITP/wiki","defaultTab":"wiki","newsList":[{"id":"2655871907","title":"Agios Reports Second Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2655871907","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655871907?lang=en_us&edition=fundamental","pubTime":"2026-07-30 18:30","pubTimestamp":1785407400,"startTime":"0","endTime":"0","summary":"Mitapivat (PYRUKYND and AQVESME) delivered worldwide net revenues of $44.7 million in the second quarter of 2026, compared to $12.5 million in the second quarter of 2025Strong U.S. commercial launch o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/30/3335866/31990/en/Agios-Reports-Second-Quarter-2026-Financial-Results-and-Provides-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4006","LU2237443549.SGD","BK4082","IE00BZ1G4Q59.USD","BK4504","LU2237443382.USD","LU0690374615.EUR","GB00B4QBRK32.GBP","ITP","LU2404859741.USD","SYK","BK4156","LU0114720955.EUR","LU2237443978.SGD","LU0170899867.USD","IHI","LU2237443622.USD","IE00BFXG1179.USD","LU1363072403.SGD","BK4566","LU0432979614.USD","LU0950375773.USD","LU2362540622.SGD","LU0882574139.USD","EC","LU0882574055.USD","LU2324357040.USD","LU0528227936.USD","LU2506951958.HKD","LU2362541273.HKD","LU2468319806.SGD","LU0971096721.USD","IE00B1BXHZ80.USD","LU0289739699.SGD","IE00BHPRN162.USD","LU2506952170.USD","LU2237443465.HKD","GCC","BK4199","LU0267386448.USD","LU2089984988.USD","LU2746668974.SGD","IE00BKVL7J92.USD","LU1791710400.SGD","LU0823417653.USD","LU2237443895.HKD","LU0058720904.USD","CMC","LU2404859667.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651441085","title":"Grifols Doses First Patients in Two Phase 3 Trials to Expand Indications of its Flagship Immunoglobulins","url":"https://stock-news.laohu8.com/highlight/detail?id=2651441085","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651441085?lang=en_us&edition=fundamental","pubTime":"2026-07-16 20:00","pubTimestamp":1784203200,"startTime":"0","endTime":"0","summary":"One trial, SIGMA, will evaluate Grifols’ intravenous immunoglobulin (Ig) GAMUNEX-C (immune globulin injection [human], 10% caprylate chromatography purified) plus standard medical treatment in patient","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/16/3328383/0/en/Grifols-Doses-First-Patients-in-Two-Phase-3-Trials-to-Expand-Indications-of-its-Flagship-Immunoglobulins.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PK","PID","BK4181","AMS","BK4139","BK4006","KBWY","BK4196","GRFS","BK4199","BK4218","SID","ITP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645818418","title":"Press Release: Bionano Announces Hiring of Chief Scientific Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2645818418","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645818418?lang=en_us&edition=fundamental","pubTime":"2026-06-24 20:30","pubTimestamp":1782304200,"startTime":"0","endTime":"0","summary":"collaborative studies to bring OGM into routine use,\" said Dr. Alexander. Hoischen, PhD, Professor of Genomic Technologies at Radboud University. Medical Center, The Netherlands. \"Having Alex Hastie back means a great. deal to the OGM community. With his in-depth understanding of the. technology, he will help guide robustness and scalability, and I am. excited to expand our collaboration for research use of Bionano's. technology from ultra-high molecular weight DNA isolation to OGM,-- \"I am delighted to see Alex Hastie return to Bionano,\" said Dr. Ying Zou,MD, PhD, FACMG, Director of the Cancer Genomics Lab at Johns Hopkins. School of Medicine. \"His deep expertise in OGM technology and proven. track record in advancing genomic research make this an exciting. development for the field. I look forward to strengthening our. collaboration to unlock new insights into cancer biology and expand the. applications of OGM across both hematologic and solid tumor. -- Dr. Rashmi Kanagal-Shamanna, M","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","ITP","BK4604","TM","BK4555","BK4199","BNGO","BK4575","BK4121","03160","BK4585","BK4099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642282351","title":"Bionano Announces Multiple Publications in 2026 Describing Unique Utility of OGM in Studies of Reproductive Health and Prenatal Genetic Disorders","url":"https://stock-news.laohu8.com/highlight/detail?id=2642282351","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642282351?lang=en_us&edition=fundamental","pubTime":"2026-06-11 20:00","pubTimestamp":1781179200,"startTime":"0","endTime":"0","summary":"Findings from 13 different studies analyzing 730 subjects to date in 2026 across multiple geographies underscore utility of OGM in key research areas including infertility, recurrent pregnancy loss, p","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/11/3310421/0/en/Bionano-Announces-Multiple-Publications-in-2026-Describing-Unique-Utility-of-OGM-in-Studies-of-Reproductive-Health-and-Prenatal-Genetic-Disorders.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4199","ITP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642067289","title":"Climb Bio Reports Encouraging Early Budoprutug ITP Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2642067289","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642067289?lang=en_us&edition=fundamental","pubTime":"2026-06-11 19:30","pubTimestamp":1781177425,"startTime":"0","endTime":"0","summary":"Climb Bio ( ($CLYM) ) has shared an update. On June 11, 2026, Climb Bio, Inc. reported initial data from the ongoing Phase 1b portion of its Phase ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/climb-bio-reports-encouraging-early-budoprutug-itp-data?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/climb-bio-reports-encouraging-early-budoprutug-itp-data?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4199","ITP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642728928","title":"Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2642728928","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642728928?lang=en_us&edition=fundamental","pubTime":"2026-06-11 19:00","pubTimestamp":1781175600,"startTime":"0","endTime":"0","summary":"Data demonstrate favorable safety and tolerability profile, robust B-cell depletion, and encouraging platelet responses in heavily pretreated patients with primary immune thrombocytopenia Enrollment o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/11/3310326/0/en/Climb-Bio-Announces-Initial-Phase-1b-Data-Demonstrating-On-Target-Clinical-Activity-for-Budoprutug-in-Immune-Thrombocytopenia-at-EHA-Congress-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ITP","BK4199","SLE","BK4077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642442360","title":"Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2642442360","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642442360?lang=en_us&edition=fundamental","pubTime":"2026-06-10 19:30","pubTimestamp":1781091000,"startTime":"0","endTime":"0","summary":"CLN-978 (CD19 TCE) EULAR data demonstrated potential for immune reset, including remissions, in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) CLN-978 data from the first RA mul","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/10/3309602/0/en/Cullinan-Therapeutics-Shares-New-Clinical-Data-Across-Its-Portfolio-of-T-Cell-Engager-Programs-Targeting-CD19-and-BCMA-in-Autoimmune-Diseases.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0963586101.USD","RA","BK4077","BK4199","CRS","IE00B7SZL793.SGD","BK4187","IE0031619046.USD","LU2065731478.USD","ITP","BK4139","CGEM","IE00B66KJ199.SGD","IE00B19Z4B17.USD","BK4006","SLE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640975548","title":"argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren’s Disease at EULAR 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2640975548","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640975548?lang=en_us&edition=fundamental","pubTime":"2026-06-03 13:00","pubTimestamp":1780462800,"startTime":"0","endTime":"0","summary":"ALKIVIA+ data in myositis indicate efgartigimod provides sustained, clinically meaningful improvements and consistent safety RHO+ data in Sjogren’s disease indicate maintenance of response following s","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/03/3305765/0/en/argenx-Presents-New-Efgartigimod-Data-Showing-Long-Term-Sustained-Patient-Benefit-in-Myositis-and-Sjogren-s-Disease-at-EULAR-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2404859741.USD","LU1914381329.SGD","LU1066051811.HKD","LU0426412945.USD","DM","GB00B4LPDJ14.GBP","LU0545562505.USD","IE000M9KFDE8.USD","ITP","LU0994945656.USD","BK4585","LU2404859667.USD","LU0265550359.USD","BK4199","LU0661504455.SGD","SG9999003800.SGD","LU0426417589.USD","BK4566","LU0314106906.USD","LU1121112475.USD","HK0000914686.HKD","BK4563","LU0738911758.USD","LU1066051225.USD","LU0690374615.EUR","HK0000914660.USD","SG9999001440.SGD","LU0690374961.EUR","LU1228905540.USD","LU0265550946.USD","BK4161","LU2381873111.SGD","SG9999011175.SGD","BK4546","GB00B4QBRK32.GBP","LU1043141396.HKD","LU1066051498.USD","LU1043141123.HKD","LU1228905037.USD","BK4075","IMNM","LU0949170772.SGD","BK4588","PM","LU1116320901.HKD","BK4139","LU1066053197.SGD","LU1506573853.SGD","LU1116320737.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640371149","title":"Agios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize Next-Generation SYK Inhibitor Cevidoplenib","url":"https://stock-news.laohu8.com/highlight/detail?id=2640371149","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640371149?lang=en_us&edition=fundamental","pubTime":"2026-06-01 17:00","pubTimestamp":1780304400,"startTime":"0","endTime":"0","summary":"Agios obtains exclusive global rights to novel, late-stage, next-generation, oral SYK inhibitor Agreement diversifies Agios’ rare hematology portfolio with expansion into immune thrombocytopenia, unlo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/01/3304100/31990/en/Agios-Enters-Exclusive-Global-License-Agreement-with-Oscotec-to-Develop-and-Commercialize-Next-Generation-SYK-Inhibitor-Cevidoplenib.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2506952097.USD","LU2746668974.SGD","IE00B1BXHZ80.USD","GB00B4QBRK32.GBP","LU2404859667.USD","BK4588","LU1791710400.SGD","LU2506951958.HKD","LU2089984988.USD","BK4566","IE00BHPRN162.USD","LU0823417653.USD","LU0882574055.USD","LU1791710582.SGD","LU2237443622.USD","BK4006","LU2506951875.HKD","LU2362541513.USD","LU0823417737.USD","LU0971096721.USD","LU0950375773.USD","LU2237443978.SGD","LU0170899867.USD","IE00BZ1G4Q59.USD","IE00BFXG1179.USD","LU0690374961.EUR","LU2324357040.USD","SYK","BK4504","LU0882574139.USD","LU2506952170.USD","GB00B4LPDJ14.GBP","LU2404859741.USD","CMC","LU0267386448.USD","LU2362541273.HKD","LU2746668461.USD","LU0114720955.EUR","LU2237443895.HKD","BK4585","LU1983299246.USD","LU2237443382.USD","LU2237443465.HKD","BK4199","LU0289739699.SGD","LU0528227936.USD","LU0149725797.USD","LU0058720904.USD","ITP","LU2468319806.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639490386","title":"InnoCare Pharma Gets Acceptance for ITP New Drug Application; Shares Up 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2639490386","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639490386?lang=en_us&edition=fundamental","pubTime":"2026-05-29 13:38","pubTimestamp":1780033123,"startTime":"0","endTime":"0","summary":"InnoCare Pharma (SHA:688428, HKG:9969) said China's drug regulator accepted the new drug application for orelabrutinib for treating primary immune thrombocytopenia (ITP), according to a Friday filing with the Shanghai bourse.Shares of the drugmaker rose 3% in recent trade on the Hong Kong bourse.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["09969","BK1574","BK4199","BK1161","BK0239","688428","ITP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638369844","title":"Bionano Announces Full Retirement of Outstanding Senior Secured Convertible Debentures","url":"https://stock-news.laohu8.com/highlight/detail?id=2638369844","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638369844?lang=en_us&edition=fundamental","pubTime":"2026-05-28 20:00","pubTimestamp":1779969600,"startTime":"0","endTime":"0","summary":"SAN DIEGO, May  28, 2026  (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it has fully retired and cancelled all outstanding Senior Secured Convertible Debentures (the \"","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/28/3302749/0/en/Bionano-Announces-Full-Retirement-of-Outstanding-Senior-Secured-Convertible-Debentures.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4199","ITP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638665093","title":"InnoCare’s ITP Drug Filing for Orelabrutinib Accepted by China Regulator","url":"https://stock-news.laohu8.com/highlight/detail?id=2638665093","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638665093?lang=en_us&edition=fundamental","pubTime":"2026-05-28 16:40","pubTimestamp":1779957628,"startTime":"0","endTime":"0","summary":"InnoCare Pharma Ltd. ( ($HK:9969) ) just unveiled an announcement. InnoCare Pharma said China’s Center for Drug Evaluation has accepted its new dru...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/innocares-itp-drug-filing-for-orelabrutinib-accepted-by-china-regulator?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/innocares-itp-drug-filing-for-orelabrutinib-accepted-by-china-regulator?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4199","ITP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638514311","title":"Bionano Announces Largest OGM Study of T-Cell Acute Lymphoblastic Leukemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2638514311","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638514311?lang=en_us&edition=fundamental","pubTime":"2026-05-26 20:00","pubTimestamp":1779796800,"startTime":"0","endTime":"0","summary":"SAN DIEGO, May  26, 2026  (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced publication of a peer-reviewed study in Modern Pathology showing that optical genome mapping (OGM) d","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/26/3301017/0/en/Bionano-Announces-Largest-OGM-Study-of-T-Cell-Acute-Lymphoblastic-Leukemia.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ITP","NGS","BK4199","BK4179"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638516292","title":"Climb Bio to Present on CLYM116 and Budoprutug Programs at European Renal Association (ERA) Congress 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2638516292","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638516292?lang=en_us&edition=fundamental","pubTime":"2026-05-26 19:00","pubTimestamp":1779793200,"startTime":"0","endTime":"0","summary":"WELLESLEY HILLS, Mass., May  26, 2026  (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, to","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/26/3300946/0/en/Climb-Bio-to-Present-on-CLYM116-and-Budoprutug-Programs-at-European-Renal-Association-ERA-Congress-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE","EPV","ITP","BK4077","BK4199"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637821452","title":"US$800 million commitment achieved by FAST-P initiative Green Investments Partnership","url":"https://stock-news.laohu8.com/highlight/detail?id=2637821452","media":"Lin Daoyi","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637821452?lang=en_us&edition=fundamental","pubTime":"2026-05-20 04:50","pubTimestamp":1779223822,"startTime":"0","endTime":"0","summary":"GIP has achieved its second close, obtaining a cumulative total of US$800 million in commitments.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"edge_highlight","url":"https://www.theedgesingapore.com/news/sustainability/us800-million-commitment-achieved-fast-p-initiative-green-investments?utm_source=Blog&utm_medium=RSS&utm_campaign=Tiger_Brokers_app_RSS","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theedgesingapore.com/news/sustainability/us800-million-commitment-achieved-fast-p-initiative-green-investments?utm_source=Blog&utm_medium=RSS&utm_campaign=Tiger_Brokers_app_RSS","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"edge_highlight","symbols":["SG9999002562.SGD","FAST","LU0577902298.EUR","SG9999014302.SGD","SG9999013486.USD","LU2238330802.EUR","LU0672654166.SGD","LU0823039010.USD","LU0096374516.USD","SG9999002406.SGD","IE00BKZH1Z71.USD","SG9999003826.SGD","LU2152927971.USD","ITP","LU0648948544.HKD","SGXZ27511609.SGD","LU0532188223.SGD","LU1522347837.USD","IE00BYQQ9H92.USD","LU0955623706.USD","LU2506951875.HKD","LU0762540952.USD","SG9999002620.SGD","LU0488056044.USD","LU0441854154.USD","LU0543330483.HKD","BK4567","LU0577902611.USD","IE00BFXG0V08.USD","LU0878004406.USD","SG9999004360.SGD","LU0831093199.SGD","SGXZ43160589.SGD","LU0011963245.USD","LU2257852520.SGD","LU1282649067.USD","BK4585","LU2506952097.USD","LU0577902454.USD","LU0261947096.USD","LU0823038988.USD","LU2506952170.USD","D05.SI","LU0950375773.USD","LU0048573645.USD","SG9999013460.SGD","LU1497734951.SGD","LU0261945553.USD","SG9999002679.SGD","SG9999001226.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635173719","title":"Climb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2635173719","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635173719?lang=en_us&edition=fundamental","pubTime":"2026-05-14 19:00","pubTimestamp":1778756400,"startTime":"0","endTime":"0","summary":"WELLESLEY HILLS, Mass., May  14, 2026  (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, to","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/14/3294750/0/en/Climb-Bio-to-Present-New-Budoprutug-Clinical-Data-at-European-Hematology-Association-EHA-2026-Congress.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EPV","ITP","SLE","BK4199","BK4077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635753938","title":"IT Tech Packaging delays Q1 Form 10-Q filing, seeks 5-day extension","url":"https://stock-news.laohu8.com/highlight/detail?id=2635753938","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635753938?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:17","pubTimestamp":1778703437,"startTime":"0","endTime":"0","summary":"IT Tech Packaging filed Form 12b-25 to notify investors it will miss deadline for quarterly Form 10-Q for period ended March 31, 2026.Filing was delayed because company could not finalize financial results or complete required disclosures without unreasonable effort or expense, limiting ability to obtain timely review of report.Company expects to file Form 10-Q within five calendar days after prescribed due date.Late-filing notice indicated no significant change in results of operations versus comparable prior-year period is expected to be reflected in earnings statements.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IT Tech Packaging Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDL8WqBM6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4199","ITP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635758016","title":"Press Release: Bionano Reports First Quarter 2026 Results and Provides a Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2635758016","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635758016?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:05","pubTimestamp":1778702700,"startTime":"0","endTime":"0","summary":"SAN DIEGO, May 13, 2026  -- Bionano Genomics, Inc.  today reported financial results for the first quarter ended March 31, 2026.\"The Bionano business is healthy, with first quarter results reflecting the continued engagement of our installed base and positive utilization trends across our optical genome mapping  and VIA software user community,\" commented Al Luderer, Ph.D., chairman and interim chief executive officer of Bionano. \"The evidence base supporting OGM continues to expand across hematologic malignancies, constitutional genetics, and cell and gene therapy applications, and we are seeing global broad-based adoption at leading institutions. We remain convinced that OGM is on a clear and accelerating path to becoming the standard for comprehensive, genome-wide structural variant analysis. Equally important, we are closing in on a meaningful balance sheet milestone - the expected retirement of our secured convertible debt - which will further strengthen our financial position and","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TM","BNGO","BK4099","03160","BK4121","BK4585","BK4604","BK4588","ITP","BK4555","BK4575","BK4199"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633453731","title":"Climb Bio Reports First Quarter 2026 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2633453731","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633453731?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:00","pubTimestamp":1778151600,"startTime":"0","endTime":"0","summary":"Robust B-cell depletion observed with budoprutug subcutaneous formulation in healthy volunteers, supporting continued development CLYM116 modeling and initial Phase 1 safety data to be presented at ER","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/07/3289829/0/en/Climb-Bio-Reports-First-Quarter-2026-Financial-Results-and-Provides-Business-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4199","BK4218","ITP","BK4181","BK4077","LU1169589451.USD","PD","BK4023","LU1169590202.USD","SLE","PK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633961311","title":"argenx Reports First Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2633961311","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633961311?lang=en_us&edition=fundamental","pubTime":"2026-05-07 13:00","pubTimestamp":1778130000,"startTime":"0","endTime":"0","summary":"$1.3 billion in first quarter global product net sales, representing 63% year-over-year growth Anti-AChR antibody negative (“seronegative”) gMG PDUFA is May 10, 2026  Management to host conference cal","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/07/3289577/0/en/argenx-Reports-First-Quarter-2026-Financial-Results-and-Provides-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0553294199.USD","LU1894683264.USD","BK4199","BK4588","LU2637428348.USD","LU0545039389.USD","BK4208","LU2346227817.USD","CMS","BK4566","GD","BK4550","BK4139","LU0661504455.SGD","LU0738911758.USD","LU0949170772.SGD","BK4187","BK4516","BK4585","LU0170899867.USD","LU1003077747.HKD","LU1894683348.USD","APM","ITP","LU2500361329.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.itpackaging.cn","stockEarnings":[{"period":"1week","weight":0.0258},{"period":"1month","weight":-0.0458},{"period":"3month","weight":-0.0672},{"period":"6month","weight":-0.1496},{"period":"1year","weight":-0.0821},{"period":"ytd","weight":-0.1815}],"compareEarnings":[{"period":"1week","weight":0.0251},{"period":"1month","weight":0.0173},{"period":"3month","weight":0.0468},{"period":"6month","weight":0.1042},{"period":"1year","weight":0.2187},{"period":"ytd","weight":0.1111}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"IT Tech Packaging, Inc., together with its subsidiaries, engages in the production and distribution of paper products in the People's Republic of China. The company operates through three segments: Dongfang Paper, Tengsheng Paper, and Baoding Shengde. It offers corrugating medium papers to companies making corrugating cardboards; and offset printing papers to printing companies. The company also provides tissue paper products, including toilet papers, boxed and soft-packed tissues, handkerchief tissues, and paper napkins, as well as bathroom and kitchen paper towels under the Dongfang Paper brand. In addition, it produces and sells non-medical single-use face masks, and medical face masks. The company was formerly known as Orient Paper, Inc. and changed its name to IT Tech Packaging, Inc. in August 2018. The company is headquartered in Baoding, the People's' Republic of China.","yearOnYearQuotes":[{"month":1,"riseRate":0.411765,"avgChangeRate":0.000296},{"month":2,"riseRate":0.352941,"avgChangeRate":-0.00011},{"month":3,"riseRate":0.176471,"avgChangeRate":-0.025315},{"month":4,"riseRate":0.352941,"avgChangeRate":0.041526},{"month":5,"riseRate":0.294118,"avgChangeRate":-0.113195},{"month":6,"riseRate":0.294118,"avgChangeRate":-0.038708},{"month":7,"riseRate":0.4375,"avgChangeRate":-0.043332},{"month":8,"riseRate":0.176471,"avgChangeRate":-0.070666},{"month":9,"riseRate":0.4375,"avgChangeRate":0.011462},{"month":10,"riseRate":0.375,"avgChangeRate":0.03598},{"month":11,"riseRate":0.375,"avgChangeRate":0.097377},{"month":12,"riseRate":0.125,"avgChangeRate":0.001262}],"exchange":"AMEX","name":"IT Tech Packaging Inc","nameEN":"IT Tech Packaging Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.0","shortVersion":"4.47.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"IT Tech Packaging Inc(ITP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest IT Tech Packaging Inc(ITP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"IT Tech Packaging Inc,ITP,IT Tech Packaging Inc股票,IT Tech Packaging Inc股票老虎,IT Tech Packaging Inc股票老虎国际,IT Tech Packaging Inc行情,IT Tech Packaging Inc股票行情,IT Tech Packaging Inc股价,IT Tech Packaging Inc股市,IT Tech Packaging Inc股票价格,IT Tech Packaging Inc股票交易,IT Tech Packaging Inc股票购买,IT Tech Packaging Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"IT Tech Packaging Inc(ITP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest IT Tech Packaging Inc(ITP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction